manjaro glp 1 agonist Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA How is Mounjaro a GLP‑1

The industry is expected to grow at a CAGR of 10.1% from 2025 to 2035

[DOI] [PubMed] [Google Scholar] 56.Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, et al

+ T cell experiment, for which a few similar studies have shown the same result, can be further explored by using additional markers to distinguish the smaller groups of T cells and observe their apoptosis ratio (Sha et al., 2024)

Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

Future research should prioritize long-term safety in underrepresented populations and strategies to mitigate lean mass loss during therapy

Although data are lacking to justify the cessation of GLP-1 RAs therapy preoperatively, additional precautions should be taken due to aspiration risk